Clinical Lab Products: Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer

Posted on

[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.0.82″ background_layout=”light” border_style=”solid” box_shadow_position=”outer”]

Biodesix’s primary immunotherapy resistance test demonstrated utility in classifying NSCLC patients treated with nivolumab by overall survival. The test classification is independent of PD-L1 status.
 
“Anti-PD-1 therapy is capable of restoring immunity and has greatly increased overall survival rates for patients. However, we know that this therapy does not benefit everyone,” says Egbert Smit, MD, PhD, a pulmonary oncologist at the Netherlands Cancer Institute and lead author of the study. “A test that can determine which patients will respond poorly to immunotherapy would greatly optimize treatment regimens.”

 

Read the full story. 

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]